Salivary gland tumors (SGT) are a group of highly heterogeneous head and neck malignancies with widely varied clinical outcomes and no standard effective treatments. The CRTC1-MAML2 fusion oncogene, encoded by a recurring chromosomal translocation t(11;19)(q14-21;p12-13), is a frequent genetic alteration found in 450% of mucoepidermoid carcinomas (MEC), the most common malignant SGT. In this study, we aimed to define the role of the CRTC1-MAML2 oncogene in the maintenance of MEC tumor growth and to investigate critical downstream target genes and pathways for therapeutic targeting of MEC. By performing gene expression analyses and functional studies via RNA interference and pharmacological modulation, we determined the importance of the CRTC1-MAML2 fusion gene and its downstream AREG-EGFR signaling in human MEC cancer cell growth and survival in vitro and in vivo using human MEC xenograft models. We found that CRTC1-MAML2 fusion oncogene was required for the growth and survival of fusion-positive human MEC cancer cells in vitro and in vivo. The CRTC1-MAML2 oncoprotein induced the upregulation of the epidermal growth factor receptor (EGFR) ligand Amphiregulin (AREG) by co-activating the transcription factor CREB, and AREG subsequently activated EGFR signaling in an autocrine manner that promoted MEC cell growth and survival. Importantly, CRTC1-MAML2-positive MEC cells were highly sensitive to EGFR signaling inhibition. Therefore, our study revealed that aberrantly activated AREG-EGFR signaling is required for CRTC1-MAML2-positive MEC cell growth and survival, suggesting that EGFR-targeted therapies will benefit patients with advanced, unresectable CRTC1-MAML2-positive MEC.
INTRODUCTION
Salivary gland tumors (SGT) are uncommon malignancies of the head and neck exhibiting varied biological behaviors.
1,2 Because of the heterogeneous nature and low prevalence, there has been a lack of large randomized controlled clinical trials for these tumors. To date, there are no standard effective diagnostics and treatments especially for patients with advanced, unresectable SGT. Therefore, a better understanding of specific genetic and epigenetic alterations associated with SGT will help with the development of targeted diagnostic and treatment strategies.
SGT is frequently characterized by recurrent chromosome translocations that result in the generation of oncogenes that participate in the pathogenesis of specific SGT. [2] [3] [4] The resulting oncogenes encode chimeric proteins with novel functions or ectopically expressed normal or truncated proteins. Each of these oncogenes, such as PLAG1, HMGA2, CRTC1-MAML2 and MYB-NFIB fusions, is associated with a specific subtype of SGT. Thus, the molecular actions and downstream effectors of these oncogenes present promising rational therapeutic opportunities for these uncommon but potentially deadly tumors.
In this study, we focused on the CRTC1-MAML2 fusion oncogene that is encoded by a recurrent chromosomal translocation t(11;19)(q14-21;p12-13) in mucoepidermoid carcinomas (MEC). [5] [6] [7] [8] [9] MEC is the most common type of salivary gland malignancy. MEC can arise from multiple other organ sites such as lung, breast, skin, esophagus, pancreas, thyroid and cervix. MEC has distinct histological features that show various mixtures of three cell types: squamous cells, mucin-secreting cells and intermediate cells. 10 Although the majority of MEC tumors are low grade that usually can be surgically removed, high-grade and some intermediate-grade tumors may develop into unresectable, lethal disease, with the 5-year survival rate of o50%. The CRTC1-MAML2 fusion is found in 450% of MEC cases. 6, 7, 11, 12 Rare cases of Warthin's tumor, the second most common salivary gland neoplasm, are also associated with CRTC1-MAML2 expression, but these tumor samples invariably contain small foci of MEC arising within the tumor mass. 5, 13 Therefore, the CRTC1-MAML2 gene fusion is highly associated with MEC. As the t (11;19) translocation is sometimes the sole cytogenetic alteration in MEC and is detected in MEC-like tumors throughout the body, CRTC1-MAML2 possibly alters common, basic molecular pathways important in MEC development in many different organ systems.
The CRTC1-MAML2 fusion gene consists of exon 1 of the CRTC1 gene (previously named MECT1/TORC1/WAMTP1) and exons [2] [3] [4] [5] of the MAML2 gene. 9, 14 CRTC1 is a member of the CREB (cAMPresponse element binding protein)-regulated transcription coactivator (CRTC) family that coactivates CREB-mediated transcription 15, 16 and plays important roles in metabolism, aging, and cancer. [17] [18] [19] MAML2 is a member of the transcriptional coactivator MAML family that has an essential role in transcriptional activation of Notch targets. 20, 21 The resulting CRTC1-MAML2 fusion contains the 42-amino-acid N-terminal CREB-binding domain of CRTC1 and the 981-amino-acid C-terminal transcriptional activation domain (TAD) of MAML2. Unlike the two individual genes CRTC1 and MAML2 that do not appear to encode endogenous transforming activity, the CRTC1-MAML2 fusion has oncogenic activity that transforms rat epithelial cells RK3E in vitro. 9, 14, 22, 23 Mechanistically, CRTC1-MAML2 fusion interacts with CREB and constitutively coactivates CREB-mediated transcription, 9, 14 which is in part required for its transforming activity in vitro.
14 CRTC1-MAML2 also displayed CREB-independent activities via coactivating activator protein-1. 24 However, the critical mediators and the role of this fusion oncogene in maintenance of MEC growth remained poorly elucidated.
In this study, we first demonstrated an essential role of CRTC1-MAML2 fusion oncoprotein in maintaining MEC cancerous phenotypes, indicating that CRTC1-MAML2 might be a promising therapeutic target. To investigate critical effector genes and pathways downstream of the fusion oncoprotein, we performed gene expression analyses and functional studies and identified an autocrine Amphiregulin (AREG)-epidermal growth factor receptor (EGFR) signaling as a downstream effector pathway of the CRTC1-MAML2 fusion oncogene, which is essential for CRTC1-MAML2-positive MEC cell growth in vitro and in vivo. We confirmed this observation by detecting marked growth inhibition of human CRTC1-MAML2-positive MEC cells in vitro and in an in vivo mouse model using the anti-EGFR antibody, Cetuximab. Our overall study demonstrates a critical role for aberrant activation of AREG-EGFR signaling in mediating oncogenic functions of the CRTC1-MAML2 fusion product. Therefore, targeted interference with this downstream AREG-EGFR signaling might be effective in blocking CRTC1-MAML2-positive cancer growth. These data support clinical evaluation of EGFR inhibitors in patients with unresectable, advanced CRTC1-MAML2-positive MEC.
RESULTS
Human MEC cells carrying the t(11;19) translocation are 'addicted' to CRTC1-MAML2 fusion oncogene expression We previously showed that the CRTC1-MAML2 fusion, but not the two unrearranged genes, was capable of inducing transformed colony formation in rat epithelial RK3E cells. 9, 14 This transforming activity of CRTC1-MAML2 results from the unique functional activity generated by the CRTC1 CREB-binding domain and the MAML2 TAD, when brought together by the t(11;19) translocation (Figure 1a) . Transient transfection of an expression vector that expressed small hairpin RNA (shRNA) against MAML2 caused a decrease in colony formation in vitro; 23 however, expression of endogenous CRTC1-MAML2 fusion in MEC cancer cells was not examined. The definite role of the CRTC1-MAML2 fusion in maintaining human MEC phenotypes remained to be determined.
Therefore, we investigated the functional consequences of depletion of endogenous CRTC1-MAML2 expression on human MEC cell growth and survival. First, we examined CRTC1-MAML2 expression in a panel of tumor cells including two fusion-positive MEC cell lines carrying the t(11;19) translocation (H3118 of salivary gland origin and H292 of lung origin, both derived from metastatic, high-grade human MEC tumors) and two fusionnegative cell lines. We verified CRTC1-MAML2 transcripts by reverse transcriptase-PCR (RT-PCR) using the primers spanning the translocation breakpoint ( Figure 1a) . We also detected endogenous CRTC1-MAML2 fusion protein (B125 kDa) in H3118 and H292 MEC cells by immunoblotting with anti-MAML2 antibodies that recognize the MAML2 TAD of the fusion (Figure 1b) . It is noted that unrearranged MAML2 expression is also detectable (B140 kDa) but at much lower levels in both fusion-positive and -negative cells (Figure 1b) .
We were unsuccessful in obtaining shRNA that exclusively knocks down CRTC1-MAML2, but found that two independent retroviral shRNAs targeting the MAML2 TAD knocked down both CRTC1-MAML2 and MAML2 (Figure 1c) . We first performed a competition assay to determine whether CRTC1-MAML2 expression is essential for the growth of MEC cells. Here, we transduced CRTC1-MAML2-positive MEC cells (H3118 and H292) and fusionnegative control cells (HSY) with the retroviruses that coexpressed shMAML2 and green fluorescent protein (GFP), or control luciferase shRNA (shLuc) and GFP. The percentage of GFP þ cells was then determined by fluorescence-activated cell sorting analysis at 3-or 4-day intervals, starting 72 h after infection (denoted as day 0) over a total time period of 11 days to detect shRNA-expressing cells. We reasoned if shRNA confers a disadvantage in cell growth, a reduction in the percentage of GFP þ cells is expected. We found that the percentage of fusion-negative cells expressing two independent shMAML2 (as indicated by GFP þ ) did not change significantly (Figure 1d ), indicating that MAML2 depletion has no effect on the growth of fusion-negative cells. In contrast, the percentage of CRTC1-MAML2 fusion-positive H3118 and H292 cells that expressed shMAML2 (causing fusion and MAML2 knockdown) progressively decreased, whereas the percentage of their control shLuc-expressing cells remained similar over the time (Figures 1e and f) . Therefore, knockdown of endogenous CRTC1-MAML2 fusion in MEC led to a growth disadvantage.
To achieve better knockdown, we next tested a pLKO.1-based lentiviral shRNA set containing five U6 promoter-regulated MAML2-specific shRNAs, and identified two good shRNAs (shM2-1 and shM2-3 targeting the 3 0 untranslated region of MAML2 and MAML2 TAD sequences, respectively) that caused knockdown of MAML2 in fusion-negative cells (not shown) and knockdown of both fusion and MAML2 in fusion-positive H3118 cells by immunoblotting (Figure 1g Figures S1a-c) , again indicating that MAML2 expression is not essential for cell growth and survival. To further distinguish the effects of fusion and MAML2 in MEC cells, we generated two independent shRNAs targeting the exon 1 of MAML2 that is not part of CRTC1-MAML2, and found that knockdown of MAML2 only, but not CRTC1-MAML2, did not affect fusion-positive MEC cell growth and survival (Supplementary Figure S2) . Therefore, these data demonstrated that a reduction in MEC cell growth and survival was because of the depletion of CRTC1-MAML2. To determine whether the biological effects caused by depletion of endogenous CRTC1-MAML2 can be rescued by exogenous CRTC1-MAML2 fusion, we generated a CRTC1-MAML2 expression construct that lacks a portion of the 3 0 untranslated region sequence that was recognized by one MAML2 shRNA (shM2-1). We introduced exogenous CRTC1-MAML2 in fusion-positive H3118 cells followed by lentiviral infection of shMAML2-1 that depleted the endogenous fusion. We found that expression of exogenous CRTC1-MAML2 partially rescued the adverse effects on cell growth and survival due to endogenous fusion depletion (Supplementary Figure S3) . Importantly, CRTC1-MAML2 cells/well in the 6-well plates under 10 and 0.2% serum concentrations for 96 h, and viable cell numbers were counted using Trypan blue (i) and apoptotic cells were measured by Annexin V/propidium iodide (PI) staining (j). Assays were performed in triplicate. *Po0.05.
(k) A total of 2 Â 10 6 luciferase-expressing H3118 MEC cells (H3118-luc) after transduction of shM2-1 or shRNA control for 48 h were injected subcutaneously to dorsal flanks of nude mice (n ¼ 8 each group). Tumor volumes were measured at different days after tumor cell injection.
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AREG is a target gene of CRTC1-MAML2 oncoprotein in human MEC cancer cells To evaluate physiological fusion target genes that are important for MEC cell growth and survival, we performed microarray analysis to compare genes that were differentially expressed caused by either overexpression of CRTC1-MAML2 in HeLa cells 22 or knockdown of endogenous fusion/MAML2 in human H3118 MEC cells by retroviral shMAML2D (Figure 1e and Supplementary  Table S1 ). One notable target gene that we identified is an EGFR ligand AREG. AREG-EGFR signaling is important in cell growth and survival. 25 Evidence also suggested that AREG-EGFR signaling might be particularly relevant for MEC, including: (1) three case reports suggested that MEC might be responsive to EGFR signaling inhibition; [26] [27] [28] (2) immunohistochemical analysis of primary human MEC tumors suggested that EGFR downstream mitogen-activated protein kinase (MAPK) signaling is activated; 29 and (3) CRTC1-MAML2-positive MEC cells, H3118 and H292, contain a wild-type EGFR gene 30 and are thus responsive to ligand stimulation. Therefore, we hypothesized that the CRTC1-MAML2 fusion oncoprotein confers MEC cells with growth and survival advantage by constitutively activating EGFR signaling through upregulation of the EGFR ligand AREG.
To test this hypothesis, we first examined AREG expression and observed higher levels of AREG transcripts and secreted AREG proteins in fusion-positive MEC cells (H3118 and H292) in comparison with fusion-negative cells (HSG and HSY) by qRT-PCR and enzyme-linked immunosorbent assay (ELISA), respectively (Figures 2a and b) . We next determined whether AREG is regulated by CRTC1-MAML2 expression level in MEC cells. We found that MAML2 knockdown in fusion-negative cells with two lentiviralbased shMAML2 (shM2-1 and shM2-3) did not significantly reduce AREG expression (Figures 2c and d) , whereas knockdown of CRTC1-MAML2 fusion (and also MAML2) with these shRNA lentiviruses in two fusion-positive H3118 and H292 MEC cells resulted in a significant reduction in AREG expression (Figures 2e-h) . Moreover, depletion of MAML2 only in H3118 cells did not affect AREG expression by qRT-PCR (not shown). Therefore, the reduction of AREG expression is because of CRTC1-MAML2 fusion knockdown. Conversely, forced expression of FLAG-tagged CRTC1-MAML2 in fusion-negative cells significantly increased AREG transcript levels (Figures 2i and j) . Importantly, we examined 13 cases of human MEC tumors (Supplementary Table S2 ) and found that AREG expression levels are significantly upregulated in fusion-positive MEC (n ¼ 7) than in fusion-negative MEC (n ¼ 6) (Figures 2k and l) . Therefore, CRTC1-MAML2 fusion upregulates AREG expression.
CRTC1-MAML2 fusion oncoprotein directly activates AREG expression via coactivating the transcription factor CREB CRTC1-MAML2 is capable of coactivating the transcription factor CREB and inducing CREB-mediated transcription.
14 Examination of the human AREG gene promoter revealed that its proximal promoter region contains a full CRE (cAMP responsive element) site ( À 64) and TATA box (Figure 3c ), suggesting that AREG is directly regulated by CRTC1-MAML2/CREB interaction. This is supported by our data showing that shRNA-mediated CREB depletion in fusion-positive H3118 MEC cells caused a reduction in AREG transcript levels by qRT-PCR (Figures 3a and b) . To determine whether CRTC1-MAML2 and CREB are physically associated with the AREG promoter, we performed chromatin immunoprecipitation (ChIP) assays using anti-CREB antibodies and anti-MAML2 antibodies as well as the negative control immunoglobulin G. We found that CREB and CRTC1-MAML2 were significantly enriched on the AREG promoter region spanning the CRE site in comparison with the control (Figure 3c ). Therefore, CRTC1-MAML2 directly binds to and activates AREG promoter via the transcription factor CREB.
EGFR signaling activation in fusion-positive MEC is dependent on the expression of CRTC1-MAML2 or AREG As CRTC1-MAML2 fusion upregulates expression of the EGFR ligand AREG, we hypothesized that CRTC1-MAML2-induced AREG binds to EGFR on MEC cells and causes constitutive activation of EGFR signaling in an autocrine manner. To investigate whether CRTC1-MAML2 expression leads to EGFR signaling activation, we determined the levels of phosphorylated forms of EGFR and the downstream target p42/p44 MAPK, the markers of active EGFR signaling, in fusion-positive and -negative cells before and after shMAML2 transduction. The levels of P-EGFR and P-p42/p44 MAPK were not affected by MAML2 knockdown in fusion-negative cells (Figure 4a ), whereas they were markedly reduced in fusionpositive cells when CRTC1-MAML2 fusion and MAML2 were depleted (Figures 4b and c) . However, P-Akt seemed unaffected (not shown). These data suggest that CRTC1-MAML2 expression is directly linked with the activation of EGFR-MAPK signaling. 
To determine the contribution of AREG upregulation to CRTC1-MAML2 fusion oncogenic functions, we investigated the effects of AREG depletion on MEC cell growth and survival. We identified two independent lentiviral-mediated AREG shRNAs (shAR-2 and -4) that were effective in depleting AREG expression in CRTC1-MAML2-positive MEC cells by qRT-PCR (Figure 4d ). AREG knockdown in fusion-positive cells significantly reduced the levels of P-EGFR and P-p42/p44 MAPK (Figure 4e) . Therefore, EGFR signaling activation in fusion-positive MEC is dependent on the expression of CRTC1-MAML2 and the downstream AREG activation. Moreover, human CRTC1-MAML2-expressing MEC xenografts resembled MEC histology based on hematoxylin and eosin staining and showed positive signals for AREG and P-p42/44MAPK in immunohistochemical analyses, further supporting active AREG-EGFR signaling in these fusion-positive MEC cells (Figures 4f and g) Depletion of AREG expression results in reduced cell growth and survival in vitro and in vivo To further define the importance of AREG upregulation in human MEC, we investigated the effects of AREG depletion on the growth and survival of CRTC1-MAML2-positive MEC cells. We found that Figure S4) . In contrast, AREG knockdown in fusion-negative HSY cells had no significant effects on cell growth and survival (Supplementary Figure S4) . Moreover, AREG knockdown significantly blocked the growth of human H3118 MEC xenografts (Figures 5d-g ). Thus, depletion of AREG expression in CRTC1-MAML2-positive MEC cells resulted in reduced cell growth and survival in vitro and blocked the growth of human MEC xenografts in vivo. These data strongly indicate that AREG, a CRTC1-MAML2 target gene, mediates activation of cellular EGFR signaling that supports MEC cancer cell growth and survival.
CRTC1-MAML2 fusion-positive MEC cancer cells are sensitive to the treatment of an anti-EGFR antibody in vitro and in vivo As we have shown that expression of the EGFR ligand AREG is enhanced by ectopic CRTC1-MAML2 overexpression and, conversely, knockdown of the CRTC1-MAML2 fusion or AREG results in reduced EGFR signaling and decreased cell growth and survival, we hypothesized that CRTC1-MAML2-positive cancer might be sensitive to EGFR signaling inhibition. Therefore, we blocked EGFR signaling using Cetuximab, an EGFR monoclonal antibody that interferes with ligand-receptor interaction. We observed that the proliferation of CRTC1-MAML2-positive MEC cells (H3118 and H292) was markedly more sensitive to Cetuximab treatment in comparison with the fusion-negative cells (HSG and HSY) (Figures 6a-d) . Western blotting confirmed that cetuximab treatment blocked active EGFR signaling as shown by reduced phospho-p42/44 MAPK levels (Supplementary Figure S5) . To validate these findings in vivo, we demonstrated that intraperitoneal injection of Cetuximab resulted in a striking growth inhibition of H3118 MEC xenograft tumor growth (Figures 6e-g ).
DISCUSSION
The CRTC1-MAML2 fusion oncogene represents a major etiologic molecular alteration in 450% of human MEC cancers, the most common malignant salivary gland tumors. Therefore, defining the functional properties and biological role of CRTC1-MAML2 will advance our understanding of salivary gland tumorigenesis and reveal new diagnostic and therapeutic targets. In this study, we demonstrated that CRTC1-MAML2 expression is required for the growth and survival of CRTC1-MAML2-positive MEC, proposing that modulating the expression or activity of the CRTC1-MAML2 fusion oncogene will be an effective therapeutic approach for blocking fusion-positive MEC. Importantly, we further identified the EGFR ligand AREG as a potential 'Achilles heel' target of the CRTC1-MAML2 fusion, as the autocrine AREG-EGFR signaling critically supports the growth and survival of CRTC1-MAML2-positive MEC cancer cells. Therefore, our studies revealed the importance of aberrantly activated CRTC1-MAML2-dependent AREG-EGFR signaling (Figure 6h) , supporting further clinical testing of anti-EGFR agents in molecularly targeted treatment of MEC.
Currently, the direct role of CRTC1-MAML2 fusion oncogene in the pathogenesis of MEC in vivo remains to be established. The CRTC1-MAML2 fusion was capable of transforming immortalized epithelial cells. 9, 14, 22, 23 Moreover, we demonstrated here a critical role of CRTC1-MAML2 in maintenance of MEC tumor growth, as its depletion caused significantly reduced cell growth and survival in vitro and in vivo in human MEC xenografts. Thus, these data showed that CRTC1-MAML2 might be important in initiating and maintaining the tumorigenic phenotype of human MEC, suggesting that the CRTC1-MAML2 fusion gene is a therapeutic target. The CRTC1-MAML2 fusion is a nuclear protein with no apparent enzymatic activity and is consequently less amenable for direct targeting intervention. A better understanding of the biology of CRTC1-MAML2 will provide new targeting opportunities. In this study, we focused on the mechanisms and significance of AREG-EGFR signaling in mediating CRTC1-MAML2 fusion oncogenic function. We showed that AREG is a CRTC1-MAML2 target gene, as it is directly induced by ectopic CRTC1-MAML2 expression and suppressed by its depletion. AREG acts in an autocrine manner and binds to functional EGFR on human MEC cells to initiate EGFR signaling, which is required for cell proliferation and survival. Thus, constitutively activated AREG-EGFR signaling in human MEC cancers presents a promising therapeutic opportunity.
AREG expression in lung cancer cells was correlated with responses to anti-EGFR cancer therapeutics. 25, 31 As we showed that fusion-positive MEC cells express elevated levels of AREG and show dependency on AREG-EGFR signaling, we subsequently tested the responses of CRTC1-MAML2-positive MEC to clinical anti-EGFR agents in comparison with fusion-negative SGT cells. Our experiments showed that CRTC1-MAML2-positive cells had greater response to the inhibition of this specific signaling pathway in vitro and in vivo using H3118 MEC xenograft. In fact, pulmonary CRTC1-MAML2-positive H292 xenograft tumors were previously found highly sensitive to Cetuximab. 32 The highly responsive nature of H292 cells was puzzling then as these cancer cells have the wild-type EGFR gene, unlike other responsive cancers with sensitizing EGFR mutations or EGFR amplification. 32, 33 Our data provided an explanation regarding H292 cell susceptibility to EGFR signaling. The contribution of EGFR mutations and gene copy gain in MEC remains unclear. However, our data strongly indicate that human CRTC1-MAML2-positive MEC tumors have upregulated AREG expression and might represent a highly responsive entity for anti-EGFR treatment, warranting further investigations into clinical testing of the efficacy of anti-EGFR treatment of fusion-positive cancers.
Mechanistically, we showed that CRTC1-MAML2-induced transcription of the AREG gene is mediated by its coactivation of CREB. Other cellular factors such as activator protein-1 might have roles in influencing CRTC1-MAML2 regulation of AREG-EGFR signaling. Constitutive activation of AREG-EGFR signaling pathway suggests that other transcription factors and target genes might cooperate, which will be important to follow-up in the future. It will also be important to elucidate cellular factors necessary for CRTC1-MAML2 activation of AREG, which could provide opportunities to block CRTC1-MAML2-induced transcription. Besides AREG-EGFR signaling, the critical downstream effectors of CRTC1-MAML2 fusion oncoprotein have not been systematically characterized in human MEC. Future efforts will be targeted at systematic evaluation of fusion-induced target genes and pathways in MEC cell proliferation, survival or migration/invasion in vitro and in vivo. The molecular signature associated with CRTC1-MAML2 fusion oncogene will be helpful in assessing tumors that allow accurate identification of distinct entities of tumors for effective therapeutic intervention. These studies may also provide new therapeutic avenues for targeting fusion-induced effectors pathways, individually or in combination.
In summary, our studies revealed an essential role of CRTC1-MAML2 in the maintenance of MEC tumor growth and identified an autocrine AREG-EGFR signaling in mediating the oncogenic functions of CRTC1-MAML2 fusion and supporting MEC 6 H3118-luc cells were injected subcutaneously to dorsal flanks of nude mice. One week later, mice with similar tumor volumes were separated into two groups, control and cetuximab treatment (n ¼ 10 each group). Cetuximab was administered via intraperitoneal (i.p.) injection at a dose of 0.2 mg (100 ml at 2 mg/ml) per mouse every 3 days. A same volume of PBS was injected as a control. Bioluminescent imaging and tumor sizes are presented (e, f). Tumor volumes were also measured daily after the treatment (g). (h) A model of CRTC1-MAML2-induced activated AREG-EGFR signaling is presented. The CRTC1-MAML2 fusion oncoprotein interacts with and coactivates the transcription factor CREB, leading to upregulation of the EGFR ligand AREG expression. The secreted AREG ligand in return activates EGFR signaling in autocrine manner that critically supports fusionpositive MEC cell growth and survival. Consequently, inhibiting AREG-EGFR signaling with anti-EGFR-targeted therapies (including antibodies that interfere with ligand-EGFR interaction or small molecules that block EGFR tyrosine kinase) might be an effective approach to block human fusion-positive MEC.
CRTC1-MAML2 oncogene induces autocrine AREG-EGFR signaling Z Chen et al cell growth and survival. Our data strongly suggest that blocking this aberrant activation of EGFR signaling will inhibit CRTC1-MAML2 fusion-positive MEC, and AREG-EGFR signaling inhibition might benefit a subset of patients with advanced and unresectable fusion-positive MEC.
MATERIALS AND METHODS

Cell culture
HSY (an immortalized parotid duct cell line), HSG (a human submandibular gland cell line), H3118 (mucoepidermoid carcinoma derived from parotid), H292 (mucoepidermoid carcinoma with pulmonary origin), 293T and 293FT were maintained in Dulbecco's modified Eagle's medium (Mediatech, Manassas, VA, USA) supplemented with 10% inactivated fetal bovine serum (FBS; Lonza, Walkersville, MD, USA) and 1% penicillin/streptomycin (Mediatech). Cells were grown at 37 1C with 5% CO 2 .
Antibodies
The following antibodies were purchased from commercial sources 
Viral transduction
To generate retroviruses, pSuperRetro-GFP/Neo constructs (shMAML2#A or shMAML2#D or shLuc) together with packing plasmid pMD.MLV and pseudotyped envelope pMD2-VSV-G were transfected to 293T cells using Superfect Transfection reagent (QIAGEN, Germantown, MD, USA). To generate lentiviruses, lentiviral constructs together with packing plasmids pCMV_dr8_91 and pMD2-VSV-G were transfected into 293FT cells. Viruses were collected at 48 and 72 h post transfection. For viral infection, targeted cells were infected on two consecutive dates with the viruses in fresh complete medium containing Polybrene (8 mg/ml; Sigma, St Louis, MO, USA) for 6-8 h, washed and replaced with fresh medium.
ELISA assays
The concentrations of secreted AREG proteins in cultured media were determined using an AREG Duo-set ELISA kit (R&D-DY262). In brief, 1 Â 10 6 cells/well were plated in the six-well plates and cultured overnight. Cells were then washed with 1 Â phosphate-buffered saline (PBS) twice and grown in 2 ml of culture medium (Dulbecco's modified Eagle's medium with 0.2% FBS) for 24 h. The media were collected and centrifuged and 1.5 ml of supernatant was collected and stored at À 20 1C for ELISA analysis. Cells were trypsinized and counted. ELISA assays were performed according to the manufacturer's protocols. Samples were run in triplicate, and secreted AREG was normalized against standard curves and presented as pg per 1 Â 10 6 cells.
Real-time RT-PCR
Real-time RT-PCR was performed as previously described. 19 RNA was isolated and reverse-transcribed into complementary DNA using a GeneAmp RNA PCR kit (Applied Biosystems, Carlsbad, CA, USA). qPCR was performed using the StepOne Real-Time PCR System with the SYBR Green PCR Core Reagents Kit (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. 
Microarray analyses
RNA samples were isolated from H3118 cells that were transduced with shMAML2D or shluc retroviruses (two biological replicates) for 72 h followed by fluorescence-activated cell sorting and then used for microarray experiments with Affymetrix human genome U133 plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) at Dana-Farber Microarray core facility (Boston, MA, USA). The data were analyzed using the dChip software from Cheng Li's lab (Boston, MA, USA). Genes with |FC|X2.0 and Po0.05 were considered differentially expressed. The microarray data were deposited in the NCBI GEO database (GSE46580).
Chromatin immunoprecipitation
ChIP assays were performed as previously described. 19 ChIP DNA was used for the real-time RT-PCR analysis using the primers flanking the CREB-binding site of the AREG promoter. The primer sequences were: forward, 5 0 -TTTTCGGGTAGCACCTTCTG-3 0 and reverse, 5 0 -CAGGTGTGCGAA CGTCTGTA-3 0 .
Western blotting analysis
Western blot analysis was performed as previously described. 34 Cell proliferation assay
The growth of control and gene-depleted cells was determined by direct cell counting. Briefly, 5 Â 10 5 /well cells were cultured in Dulbecco's modified Eagle's medium containing 10% FBS or 0.2% FBS in the six-well plates, and the cell numbers were scored by Trypan blue exclusion assays after culture for 96 h. The effects of Cetuximab on cancer cell proliferation were evaluated using MTS assay (Promega, Madison, WI, USA). Briefly, exponentially growing cells were seeded into 96-well plates at 1000 cells/ well in 0.1 ml of medium containing various concentrations of Cetuximab for 72 h at 37 1C. Triplicate assays were set up. MTS assays were performed by adding 20 ml of MTS (1 mg/ml) to each well and incubating for 4 h at 37 1C to allow MTS to form formazan crystals by reacting with metabolically active cells. The absorbance was measured in a micro-plate reader at 490 nm. The percentage cell growth was calculated by the comparison of the absorbance reading obtained from treated versus control cells.
Apoptosis assay
Fluorescein isothiocyanate Annexin V staining followed by flow cytometric analysis was performed to detect apoptotic cells. In brief, 5 Â 10 5 /well cells were cultured in Dulbecco's modified Eagle's medium containing 10 or 0.2% FBS in the six-well plates for 96 h. Cells were trypsinized and washed once with cold 1 Â PBS. Cell pellet was resuspended in 100 ml 1 Â binding buffer together with 5 ml of fluorescein isothiocyanate Annexin V and 5 ml of propidium iodide. Cells were incubated for 15 min at room temperature in the dark after being gently vortexed and then were subjected to flow cytometric analysis.
Mouse xenograft studies
Tumor xenograft studies were performed following a protocol approved by institutional animal care and use committee of the University of Florida. H3118 cells expressing firefly luciferase (H3118-luc) were infected with control shRNA or shAREG lentiviruses. Then, 2 Â 10 6 of these cells were diluted in 100 ml 50% Matrigel (BD Biosciences)/PBS and injected subcutaneously into the left flank of B8-week-old female NCR nude mice (Taconic, Germantown, NY, USA). Tumor volumes were measured daily by Dial Caliper and bioluminescence images were taken weekly. Tumor volumes were calculated using the formula: tumor volume ¼ (length Â width 2 ) Â 0.5. For bioluminescence imaging, mice were given 150 mg/g of D-luciferin in PBS by intraperitoneal injection. After 15 min of injection, bioluminescence was imaged with a Xenogen In vivo Imaging System (Caliper Life Sciences, Hopkinton, MA, USA).
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